Predictors of recurrence after conversion therapy in unresectable hepatocellular carcinoma treated with HAIC, bevacizumab, and sintilimab
Decline ratios of tumor size and AFP during HAIC + bevacizumab + sintilimab conversion therapy were robust and independent predictors of 1-year postoperative recurrence in HCC. Monitoring of these dynamic biomarkers may guide optimal surgical timing and follow-up strategies.
Authors
- Shi-Bo Zhu
- Zhao Xiao-hui
- Yu Haipeng
- Changfu Liu
- Wenge Xing (ORCID: https://orcid.org/0000-0003-3882-2934)
- Huikai Li
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-26
- DOI
- https://doi.org/10.3389/fimmu.2025.1644570
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Tianjin Medical University
- Tianjin Municipal Education Commission
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences